CytomX Therapeutics, Inc. (CTMX) Return on equity 2016–2025
CytomX Therapeutics, Inc. (CTMX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-17.5%FY2025 · since FY2016: -75.1% → -17.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -17.5% | — |
| FY2019 | -521.5% | -459.2 pp |
| FY2018 | -62.3% | -0.6 pp |
| FY2017 | -61.7% | +13.4 pp |
| FY2016 | -75.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CTMX financial trends
CTMX RevenueCTMX Net incomeCTMX Net marginCTMX Gross profitCTMX Gross marginCTMX Operating incomeCTMX Operating marginCTMX Operating cash flowCTMX Free cash flowCTMX Capital expendituresCTMX Stock buybacksCTMX Dividends paidCTMX Total assetsCTMX Total liabilitiesCTMX Shareholders’ equityCTMX overview →